The Motley Fool. DATE Monday, July 14, 2025 at 5 p.m. EDT CALL PARTICIPANTS Chief Executive Officer -- Shawn O'ConnorChief ...

Simulations Plus dipped after Q3 2025 on guidance cuts, but core software strength and long-term growth drivers remain. Find ...

Fintel reports that on July 15, 2025, Keybanc downgraded their outlook for Simulations Plus (NasdaqGS:SLP) from Overweight to ...

Simulations Plus Inc. reported lower than expected sales and reduced guidance due to cautious biopharma spending.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $26.5, a high estimate of $36.00, and a low estimate of $20.00. This current average represents a 31.17% ...

RESEARCH TRIANGLE PARK, N.C. (AP) — RESEARCH TRIANGLE PARK, N.C. (AP) — Simulations Plus Inc. (SLP) on Monday reported a loss of $67.3 million in its fiscal third quarter.

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications ...

Simulations Plus growth is steady, but its margins continue to decline. Check out why I remain neutral on SLP stock.

Simulations Plus beat earnings, with revenues hitting US$13m, ahead of expectations, and statutory earnings per share outperforming analyst reckonings by a solid 11%.

Simulations Plus has reported impressive financial results for the first quarter of fiscal 2025, with a notable 31% year-over-year revenue growth, primarily driven by robust software sales.

Simulations Plus (SLP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Simulations Plus has a long track record of delivering consistent growth and margin expansion. However, the stock has been down due to concerns about the funding environment for biotechnology and ...